 SAN DIEGO, Feb. 17, 2022 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kuras management will host a webcast and conference call at 4:30 p.m. ET 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. 